# Diabetes â€“ Insulin

This is a subcategory of Endocrine Agents.

## Formulary

### Preferred

| Preferred                               |
| :-------------------------------------- |
| Apidra                                  |
| Humalog 50-50                           |
| Humalog 75-25                           |
| Humalog U-100                           |
| Humulin 70-30                           |
| Humulin R U-500                         |
| Insulin Aspart                          |
| Insulin Aspart Protamine/Insulin Aspart |
| Insulin Lispro                          |
| Lantus BvG                              |
| Levemir                                 |
| Novolog 70-30                           |
| Novolog U-100                           |
| Toujeo                                  |
| Tresiba ST                              |

### Non-Preferred

| Non-Preferred    |
| :--------------- |
| Admelog          |
| Afrezza          |
| Basaglar         |
| Fiasp            |
| Humalog U-200    |
| Humulin N U-100  |
| Humulin R U-100  |
| Insulin glargine |
| Lyumjev          |
| Novolin 70-30    |
| Novolin N U-100  |
| Novolin R U-100  |

## Length of Authorizations

365 Days

## Prior Authorization Criteria

1.  Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
    -   Allergy to medications not requiring prior approval
    -   Contraindication to or drug interaction with medications not requiring prior approval
    -   History of unacceptable/toxic side effects to medications not requiring prior approval
    -   Condition is difficult to control (i.e. prone to ketoacidosis, hypoglycemia)
2.  For a medication requiring step therapy, there must have been an inadequate clinical response to at least **one** preferred medication within the same class not requiring prior authorization. A therapeutic failure is the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.
3.  The requested non-preferred medication may be approved if there has been a therapeutic failure to at least **two** medications within the same class not requiring prior authorization. A therapeutic failure is the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.

## Additional Criteria

### Inhaled Insulin

Additional Clinical Criteria for Inhaled Insulin

-   Patient has a claim for a long-acting insulin in the previous 120 days, or patient has type 2 diabetes; and
-   Patient has not been diagnosed with asthma or COPD; and
-   Spirometry shows FEV1 \> / = 70% predicted; and
-   Patient has not smoked for at least 180 days

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=50)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=20)
